drugset / Trial / NCT01318109

Efficacy and Safety of Alogliptin Used Combination With Metformin in Participants With Type 2 Diabetes in Japan

NCT01318109

Phase 2/3 Completed 288 enrolled Takeda
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study was evaluate the efficacy and safety of alogliptin, once dairy (QD) combined with metformin taken twice daily (BID) or three times daily (TID) in type 2 diabetic patients with uncontrolled blood glucose.

Timeline

Start
2008-08
Primary completion
2009-04
Completion
2009-04

Drugs

EvaluationDrugModalityDoseRoute
Comparator Alogliptin Unknown 12.5 mg Oral
Comparator Alogliptin Unknown 25 mg Oral
Comparator Metformin Small molecule 250 mg Oral